NCT05169424View on ClinicalTrials.gov

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

CompletedOBSERVATIONAL
Enrollment

9,117

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

December 27, 2021

Study Completion Date

December 27, 2021

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DEVICE

Trelegy Ellipta

Trelegy Ellipta

DEVICE

Stiolto Respimat

Stiolto Respimat

DRUG

Tiotropium + Olodaterol (5/5 mcg)

Tiotropium + Olodaterol (5/5 mcg)

DRUG

Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

Trial Locations (1)

10601

eMax health, White Plains

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY